Physician profile
Leonard E Maliver
NPI 1548215353
$9,153.43
in general payments reported to CMS, 2019-2025
32 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,509 · 2020: $876 · 2021: $2,293 · 2022: $2,892 · 2023: $1,017 · 2024: $420 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,968.86 | 2020-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $1,853.55 | 2021-2025 | Interstim |
| Astellas Pharma US INC | $1,203.18 | 2019-2024 | Myrbetriq, Xtandi |
| Pfizer INC. | $529.33 | 2019-2025 | |
| Cook Medical LLC | $525.91 | 2019 | |
| Cook Incorporated | $485.74 | 2019 | |
| Janssen Biotech, INC. | $472.42 | 2019-2025 | Erleada |
| Sumitomo Pharma America, INC. | $417.19 | 2023-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $299.80 | 2021-2023 | Urolift |
| Neotract INC. | $167.35 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $159.69 | 2019-2023 | Caldolor |
| Urovant Sciences INC | $127.93 | 2021-2022 | |
| Antares Pharma, INC. | $113.11 | 2023 | Nocdurna, Xyosted, Tlando |
| Boston Scientific Corporation | $105.62 | 2020-2025 | Rezum Generator, Axonics |
| Abbvie INC. | $96.77 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dentsply Ih INC. | $87.50 | 2019-2021 | |
| Medtronic USA, INC. | $69.21 | 2019-2020 | |
| Dornier Medtech America, INC | $57.04 | 2022 | |
| Myovant Sciences INC. | $55.69 | 2021-2022 | |
| Amgen INC. | $53.26 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $47.79 | 2020-2022 | |
| Preventice Services, LLC | $42.41 | 2021 | |
| Halozyme INC | $39.98 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $36.44 | 2021 | |
| Ferring Pharmaceuticals INC. | $33.26 | 2024 | Adstiladrin |
| Convatec INC. | $20.46 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.59 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.35 | 2022 | |
| Olympus America INC. | $17.26 | 2025 | Itind System |
| Neurelis, INC. | $15.92 | 2022 | |
| Allergan, INC. | $13.82 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Maliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.